Sullivan NJ - Search Results

1

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Misasi J, et al. Among authors: sullivan nj. Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25. Science. 2016. PMID: 26917592 Free PMC article.

2

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Yang ZY, et al. Among authors: sullivan nj. Nat Med. 2000 Aug;6(8):886-9. doi: 10.1038/78645. Nat Med. 2000. PMID: 10932225

3

Development of a preventive vaccine for Ebola virus infection in primates.

Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Sullivan NJ, et al. Nature. 2000 Nov 30;408(6812):605-9. doi: 10.1038/35046108. Nature. 2000. PMID: 11117750

4

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Sullivan NJ, et al. Nature. 2003 Aug 7;424(6949):681-4. doi: 10.1038/nature01876. Nature. 2003. PMID: 12904795 Free PMC article.

5

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Chandran K, et al. Among authors: sullivan nj. Science. 2005 Jun 10;308(5728):1643-5. doi: 10.1126/science.1110656. Epub 2005 Apr 14. Science. 2005. PMID: 15831716 Free PMC article.

6

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. Sullivan NJ, et al. PLoS Med. 2006 Jun;3(6):e177. doi: 10.1371/journal.pmed.0030177. Epub 2006 May 16. PLoS Med. 2006. PMID: 16683867 Free PMC article.

7

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. Martin JE, et al. Among authors: sullivan nj. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. doi: 10.1128/CVI.00162-06. Epub 2006 Sep 20. Clin Vaccine Immunol. 2006. PMID: 16988008 Free PMC article. Clinical Trial.

8

Immunopathology of highly virulent pathogens: insights from Ebola virus.

Zampieri CA, Sullivan NJ, Nabel GJ. Zampieri CA, et al. Among authors: sullivan nj. Nat Immunol. 2007 Nov;8(11):1159-64. doi: 10.1038/ni1519. Nat Immunol. 2007. PMID: 17952040 Free PMC article. Review.

9

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Sullivan NJ, et al. Nat Rev Microbiol. 2009 May;7(5):393-400. doi: 10.1038/nrmicro2129. Nat Rev Microbiol. 2009. PMID: 19369954 Free PMC article. Review.

10

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.

Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Shedlock DJ, et al. Among authors: sullivan nj. Virology. 2010 Jun 5;401(2):228-35. doi: 10.1016/j.virol.2010.02.029. Epub 2010 Mar 20. Virology. 2010. PMID: 20304456 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

186 results

Search Page